Online ISSN: 2149-3189
2015
Monthly
Nicaea Medical Publishing
Türkiye

Three Decades of SSRI/SNRI Withdrawal Research: A Bibliometric and Science-Mapping Study

Erdoğdu Akça
DOI
https://doi.org/10.18621/eurj.1825803
Abstract
Objectives: Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) are widely prescribed, and growing evidence highlights the clinical and methodological challenges of withdrawal during discontinuation. This study aimed to provide a comprehensive bibliometric map of SSRI/SNRI withdrawal research to clarify production patterns, citation structures, thematic evolution, and global collaboration.
Methods: A comprehensive search of the Web of Science Core Collection (1995–2025) identified 652 original articles on SSRI/SNRI withdrawal, discontinuation, or tapering. Records were analyzed using the bibliometrix package in R for performance metrics, co-citation and keyword networks, and country–institution collaboration structures.
Results: The corpus comprised 652 documents published in 308 journals, citing 18,957 references, with an annual growth rate of 7.79%. Articles received a mean of 41.6 citations. The Journal of Clinical Psychiatry (22 articles; h=20) and Journal of Clinical Psychopharmacology (18; h=14) were the most influential sources. Highly cited documents ranged from 270 to 730 citations, predominantly from Lancet, Pediatrics, The New England Journal of Medicine, and American Journal of Psychiatry. Keyword frequency was led by “depression” (n=172), “fluoxetine” (n=153), and “antidepressants” (n=152). The United States produced 240 articles (36.8%; 12,904 citations), forming the central hub of the collaboration network.
Conclusions: SSRI/SNRI withdrawal research shows concentrated authorship, journal anchoring, and geographically centralized knowledge production, with emerging themes in tapering, pregnancy outcomes, and pharmacogenetics.
Keywords
Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Withdrawal, Discontinuation, Tapering, Bibliometric
References

1. Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524.

2. Chouinard G, Chouinard VA. New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychother Psychosom. 2015;84(2):63-71. doi: 10.1159/000371865.

3. Gastaldon C, Schoretsanitis G, Arzenton E, et al. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database. Drug Saf. 2022;45(12):1539-1549. doi: 10.1007/s40264-022-01246-4.

4. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008;22(3):330-332. doi: 10.1177/0269881107081550.

5. Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007;10(1):73-84. doi: 10.1017/S1461145705006358.

6. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom. 2015;84(2):72-81. doi: 10.1159/000370338.

7. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav. 2019;97:111-121. doi: 10.1016/j.addbeh.2018.08.027.

8. Glänzel W. Bibliometrics as a Research Field. A course on theory and application of bibliometric indicators. Course Handouts. 2003.

9. Small H. Co‐citation in the scientific literature: A new measure of the relationship between two documents. J Am Soc Inf Sci. 1973;24(4):265-269. doi: 10.1002/asi.4630240406.

10. Klarin A. How to conduct a bibliometric content analysis: Guidelines and contributions of content co-occurrence or co-word literature reviews. Int J Consum Stud. 2024;48(2):e13031. doi:10.1111/ijcs.13031.

11. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res. 2021;133:285-296. doi:10.1016/j.jbusres.2021.04.070.

12. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom. 2016;85(5):270-288. doi: 10.1159/000447034.

13. Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence. 2016;10:1401-1407. doi: 10.2147/PPA.S110632.

14. Read J, Williams J. Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects. Curr Drug Saf. 2018;13(3):176-186. doi: 10.2174/1574886313666180605095130.

15. Bosman RC, Huijbregts KM, Verhaak PF, et al. Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care. Br J Gen Pract. 2016;66(651):e708-719. doi: 10.3399/bjgp16X686641.

16. Zupic I, Čater T. Bibliometric methods in management and organization. Organ. Res. Methods. 2015;18(3):429-472. doi: 10.1177/10944281145626.

17. Mongeon P, Paul-Hus A. The journal coverage of Web of Science and Scopus: a comparative analysis. Scientometrics. 2016;106(1):213-228. doi:10.1007/s11192-015-1765-5

18. Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959-975. doi:10.1016/j.joi.2017.08.007

19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. doi: 10.1192/bjp.134.4.382.

20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi: 10.1136/jnnp.23.1.56.

21. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77-87. doi: 10.1016/s0006-3223(98)00126-7.

22. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339. doi: 10.1001/archpsyc.63.3.332.

23. Whittington CJ, Kendall T, Pilling S. Are the SSRIs and atypical antidepressants safe and effective for children and adolescents? Curr Opin Psychiatry. 2005;18(1):21-25.

24. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156(11):1129-1132. doi: 10.1001/archpedi.156.11.1129.

25. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372-2383. doi: 10.1001/jama.293.19.2372.

26. Biernacka JM, Sangkuhl K, Jenkins G, et al. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry. 2015;5(4):e553. doi: 10.1038/tp.2015.47.

27. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538-546. doi: 10.1016/S2215-0366(19)30032-X.

28. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006;67 Suppl 4:27-30.

29. Kaymaz N, van Os J, Loonen AJ, Nolen WA. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2008;69(9):1423-1436. doi: 10.4088/jcp.v69n0910.

30. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587. doi: 10.1056/NEJMoa052744.

31. Hudak ML, Tan RC, Frattarelli DAC, et al. Neonatal Drug Withdrawal. Pediatrics. 2012;129(2):e540-e560.

32. Fava GA, Cosci F. Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. J Clin Psychiatry. 2019;80(6):19com12794. doi: 10.4088/JCP.19com12794.

33. Papakostas GI, Perlis RH, Seifert C, Fava M. Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychother Psychosom. 2007;76(5):266-270. doi: 10.1159/000104702.

34. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1205-1215. doi: 10.1097/00004583-200210000-00010.

35. FDA. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications.

36. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry. 1991;48(8):730-738. doi: 10.1001/archpsyc.1991.01810320054008.

37. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998;155(1):36-42. doi: 10.1176/ajp.155.1.36.

38. Andrade SE, Reichman ME, Mott K, et al. Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program. Arch Womens Ment Health. 2016;19(6):969-977. doi: 10.1007/s00737-016-0637-1.

39. Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. Am J Psychiatry. 2018;175(5):463-470. doi: 10.1176/appi.ajp.2017.17050550.

There are 39 references in total.
How to Cite
1.
Akça E. Three Decades of SSRI/SNRI Withdrawal Research: A Bibliometric and Science-Mapping Study. Eur Res J. 2026;12(2):256-271. doi:10.18621/eurj.1825803
License
Creative Commons License

Copyright (c) 2026 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

View Volume 12 - Issue 2 (February 2026)

Volume 12 - Issue 2 (February 2026)

Article Information

  • File Downloads 106
  • Abstract Views 136
  • Altmetrics
  • Share
Download data is not yet available.